FibroBiologics to Present at the Advanced Wound Care Summit USA
11 Jul 2025 12:30 GMT
…
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China
09 Jul 2025 13:00 GMT
… , LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or …
FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10
07 Jul 2025 20:35 GMT
…
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
NervGen Engages Russo Partners LLC to Provide Public Relations Services
25 Apr 2024 23:32 GMT
… . For more information, visit www.russopartnersllc.com or follow Russo Partners on … Partners
david.schull@russopartnersllc.com
ignacio.guerrero-ros@russopartnersllc.com
858.717.2310
646 …
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
30 Jun 2025 20:05 GMT
… and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256
Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial
24 Jun 2025 13:15 GMT
… , LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or …
iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
24 Jun 2025 11:00 GMT
… , LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or …
iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call
23 Jun 2025 20:15 GMT
… , LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or …